Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Die Folgen des Klimwandels haben einen direkten Einfluss auf die Primärversorgung in Deutschland: Hitzeschutz insbesondere bei älteren Patienten, die Zunahme von Infektionen und die Verlängerung der Allergiesesaison spielen medizinisch eine bedeutsame Rolle. Aber auch in der Prävention und der Aufklärung der Patienten kommt den Hausärztinnen und -ärzten eine besondere Rolle zu. Direkt aus der Praxis berichtet im Live-Webinar am 13. Mai von 18 bis 19 Uhr unser Experte Dr. med. Robin Maitra.
Erweiterte Suche
Anmelden
nach oben
Clinical & Experimental Metastasis
Erschienen in: Clinical & Experimental Metastasis 5-6/2018

02.05.2018 | Review

Review of diagnostic, prognostic, and predictive biomarkers in melanoma

verfasst von: Jacob S. Ankeny, Brian Labadie, Jason Luke, Eddy Hsueh, Jane Messina, Jonathan S. Zager

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5-6/2018

Einloggen, um Zugang zu erhalten

Abstract

Melanoma is an aggressive cutaneous malignancy with rapidly rising incidence. Diagnosis of controversial melanocytic lesions, correct prognostication of patients, selection of appropriate adjuvant and systemic therapies, and prediction of response to a given therapy remain very real challenges. Despite these challenges, multiple high throughput, nucleic-acid based biomarkers have been developed that can be assayed from histologic tissue specimens. FISH, CGH, Decision-Dx, and other multi-marker assays have been combined to improve overall predictability. This review discusses some of the most promising nucleic acid based assays that can be obtained from tissue specimens to assist with diagnosis, prognostication, and prediction of treatment response.
Literatur
1.
Siegel RL, Miller KD, Jemal A (2017) Cancer statistics. CA Cancer J Clin 67(1):7–30CrossRef
2.
Gimotty PA, Guerry D (2010) Prognostication in thin cutaneous melanomas. Arch Pathol Lab Med 134(12):1758–1763PubMed
3.
Whiteman DC, Baade PD, Olsen CM (2015) More people die from thin melanomas (1 mm) than from thick melanomas (> 4 mm) in Queensland, Australia. J Invest Dermatol 135(4):1190–1193CrossRef
4.
Wong SL et al (2005) A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system. Ann Surg Oncol 12(4):282–288CrossRef
5.
Mahar AL, McShane LM, Groome PA, Compton CC (2013) A survey of clinical prediction tools in colorectal and lung cancers and melanoma. J Clin Oncol 31(15S): 1592
6.
Mahar AL et al (2016) Critical assessment of clinical prognostic tools in melanoma. Ann Surg Oncol 23(9):2753–2761CrossRef
7.
Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 101(7):452–474CrossRef
8.
Schramm SJ, Mann GJ (2011) Melanoma prognosis: a REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10(8):1520–1528CrossRef
9.
Gould Rothberg BE et al (2009) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27(34):5772–5780CrossRef
10.
Piras F et al (2008) Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 20(2):271–277PubMed
11.
Kashani-Sabet M et al (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15(22):6987–6992CrossRef
12.
Gerami P et al (2015) Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Clin Cancer Res 21(1):175–183CrossRef
13.
Gerami P et al (2015) Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol 72(5):780–785.e3CrossRef
14.
Gerami P et al (2009) Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 33(8):1146–1156CrossRef
15.
Scolyer RA et al (2010) Histologically ambiguous (“borderline”) primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. Arch Pathol Lab Med 134(12):1770–1777PubMed
16.
Dalton SR et al (2010) Use of fluorescence in situ hybridization (FISH) to distinguish intranodal nevus from metastatic melanoma. Am J Surg Pathol 34(2):231–237CrossRef
17.
Pouryazdanparast P et al (2009) Distinguishing epithelioid blue nevus from blue nevus-like cutaneous melanoma metastasis using fluorescence in situ hybridization. Am J Surg Pathol 33(9):1396–1400CrossRef
18.
Gerami P et al (2009) Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol 33(12):1783–1788CrossRef
19.
Gerami P et al (2012) A highly specific and discriminatory FISH assay for distinguishing between benign and malignant melanocytic neoplasms. Am J Surg Pathol 36(6):808–817CrossRef
20.
Gaiser T et al (2010) Classifying ambiguous melanocytic lesions with FISH and correlation with clinical long-term follow up. Mod Pathol 23(3):413–419CrossRef
21.
Massi D et al (2011) Atypical Spitzoid melanocytic tumors: a morphological, mutational, and FISH analysis. J Am Acad Dermatol 64(5):919–935CrossRef
22.
Tetzlaff MT et al (2013) Ambiguous melanocytic tumors in a tertiary referral center: the contribution of fluorescence in situ hybridization (FISH) to conventional histopathologic and immunophenotypic analyses. Am J Surg Pathol 37(12):1783–1796CrossRef
23.
Vergier B et al (2011) Fluorescence in situ hybridization, a diagnostic aid in ambiguous melanocytic tumors: European study of 113 cases. Mod Pathol 24(5):613–623CrossRef
24.
Bauer J, Bastian BC (2006) Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 19(1):40–49CrossRef
25.
Bastian BC et al (1998) Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 58(10):2170–2175
26.
Ali L et al. (2010) Correlating array comparative genomic hybridization findings with histology and outcome in spitzoid melanocytic neoplasms. Int J Clin Exp Pathol 3(6): 593–599
27.
Bastian BC et al (2003) Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 163(5):1765–1770CrossRef
28.
Clarke LE et al (2015) Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. J Cutan Pathol 42(4):244–252CrossRef
29.
Minca EC et al (2016) Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions. Mod Pathol 29(8):832–843CrossRef
30.
Network NCC (2018) NCCN Guidelines Version 2.2018, in NCCN Clnical Practice Guidelines in Oncology. Coit DG (ed) National Comprehensive Cancer Network
31.
Abbas O, Miller DD, Bhawan J (2014) Cutaneous malignant melanoma: update on diagnostic and prognostic biomarkers. Am J Dermatopathol 36(5):363–379CrossRef
32.
Adler NR et al (2017) Metastatic pathways in patients with cutaneous melanoma. Pigment Cell Melanoma Res 30(1):13–27CrossRef
33.
Nodin B et al (2012) High MCM3 expression is an independent biomarker of poor prognosis and correlates with reduced RBM3 expression in a prospective cohort of malignant melanoma. Diagn Pathol 7:82CrossRef
34.
Nielsen PS et al (2013) Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma. Mod Pathol 26(3):404–413CrossRef
35.
Donizy P et al (2016) Golgi-related proteins GOLPH2 (GP73/GOLM1) and GOLPH3 (GOPP1/MIDAS) in cutaneous melanoma: patterns of expression and prognostic significance. Int J Mol Sci 17(10):1619CrossRef
36.
Fohn LE et al (2011) D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: association with sentinel lymph node status and prognostic value-a retrospective case study. J Am Acad Dermatol 64(2):336–345CrossRef
37.
Han D et al (2013) Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 31(35):4387–4393CrossRef
38.
Rangel J et al (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112(1):144–150CrossRef
39.
Rangel J et al (2008) Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32(8):1207–1212CrossRef
40.
Leiter U et al (2016) Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol 17(6):757–767CrossRef
41.
Faries MB et al (2017) Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med 376(23):2211–2222CrossRef
42.
Damude S et al (2016) The predictive power of serum S-100B for non-sentinel node positivity in melanoma patients. Eur J Surg Oncol 42(4):545–551CrossRef
43.
Wevers KP et al (2013) Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. Eur J Surg Oncol 39(2):179–184CrossRef
44.
van der Ploeg AP et al (2011) Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29(16):2206–2214CrossRef
45.
Pastushenko I et al (2016) Increased angiogenesis and lymphangiogenesis in metastatic sentinel lymph nodes is associated with nonsentinel lymph node involvement and distant metastasis in patients with melanoma. Am J Dermatopathol 38(5):338–346CrossRef
46.
Veronesi U et al (1988) Thin stage I primary cutaneous malignant melanoma: comparison of excision with margins of 1 or 3 cm. N Engl J Med 318(18):1159–1162CrossRef
47.
Ringborg U et al (1996) Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer 77(9):1809–1814CrossRef
48.
Balch CM et al (2001) Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1–4 mm melanomas. Ann Surg Oncol 8(2):101–108PubMed
49.
Thomas JM et al (2004) Excision margins in high-risk malignant melanoma. N Engl J Med 350(8):757–766CrossRef
50.
Gillgren P et al (2011) 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 378(9803):1635–1642CrossRef
51.
Doepker MP et al (2016) Is a wider margin (2 cm vs. 1 cm) for a 1.01-2.0 mm melanoma necessary? Ann Surg Oncol 23(7):2336–2342CrossRef
52.
Hsueh EC et al (2017) Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test. J Hematol Oncol 10(1):152CrossRef
53.
Zager JS et al (2018) Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. BMC Cancer 18(1):130CrossRef
54.
Ferris LK et al (2017) Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification. J Am Acad Dermatol 76(5):818–825 e3CrossRef
55.
Eggermont AM et al (2015) Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol 16(5):522–530CrossRef
56.
Weber J et al (2017) Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med 377(19):1824–1835CrossRef
57.
Long GV et al (2017) Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med 377(19):1813–1823CrossRef
58.
Wolchok JD et al (2017) Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377(14):1345–1356CrossRef
59.
Hodi FS et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363(8):711–723CrossRef
60.
Robert C et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521–2532CrossRef
61.
Robert C et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39CrossRef
62.
Larkin J et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867–1876CrossRef
63.
Luke JJ et al (2017) Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol 14(8):463–482CrossRef
64.
Daud AI et al (2016) Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34(34):4102–4109CrossRef
65.
Snyder A et al (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371(23):2189–2199CrossRef
66.
Johnson DB et al (2016) Targeted next generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunol Res 4(11):959–967CrossRef
67.
Harlin H et al (2009) Chemokine expression in melanoma metastases associated with CD8 + T-cell recruitment. Cancer Res 69(7):3077–3085CrossRef
68.
Ji RR et al (2012) An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 61(7):1019–1031CrossRef
69.
Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14(10):1014–1022CrossRef
70.
Ayers M et al (2017) IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 127(8):2930–2940CrossRef
Metadaten
Titel
Review of diagnostic, prognostic, and predictive biomarkers in melanoma
verfasst von
Jacob S. Ankeny
Brian Labadie
Jason Luke
Eddy Hsueh
Jane Messina
Jonathan S. Zager
Publikationsdatum
02.05.2018
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 5-6/2018
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-018-9892-z

Weitere Artikel der Ausgabe 5-6/2018

Clinical & Experimental Metastasis 5-6/2018 Zur Ausgabe

Research Paper

Metastatic gynecologic malignancies: advances in treatment and management

Review

Sentinel node evaluation in prostate cancer

Review

Update on the indications and results of sentinel node mapping in upper GI cancer

Research Paper

Breast cancer metastasis through the lympho-vascular system

Research Paper

Regional therapies for locoregionally advanced and unresectable melanoma

Research Paper

Lymphedema following cancer therapy: overview and options

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise